The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ESH MM 2018 | Updated CASTOR analysis: daratumumab plus Vd for R/R myeloma
Maria-Victoria Mateos, MD, PhD, of the University of Salamanca, Salamanca, Spain, discusses the updated analysis of the CASTOR trial (NCT02136134) with us at the European School of Haematology (ESH) International Conference on Multiple Myeloma 2018, held in Mandelieu, France. This trial investigated daratumumab plus bortezomib/dexamethasone for relapsed/refractory multiple myeloma, and this follow-up showed excellent response rates and survival benefit, in addition to indicating the group that will receive the maximum benefit from this regimen.
